December 3, 2017 – By Winifred Garcia
Investor confidence decreased to 0.88 in the second quarter of 2017. Its decline is 0.75, from 1.63 in 2017Q1. He plunged, as 69 investors sold shares of Abbott Laboratories while 545 shares declined. 102 funds opened positions, while 441 increased positions. 1.22 billion shares or 0.83% more than 1.21 billion shares were reported in 2017Q1.
Bbva Compbad Savings Bank Inc has 231,381 shares for 0.74% of its portfolio. Homrich & Berg has 0.04% invested in Abbott Laboratories (NYSE: ABT). Dearborn Prtn Lc owns 0.22% of its portfolio at Abbott Laboratories (NYSE: ABT) for 62,212 shares. Arete Wealth Limited Liability Co owns 0.2% invested in Abbott Laboratories (NYSE: ABT) for 9,192 shares. Ubs Asset Management Americas owns 7.69 million shares. Usca Ria Limited Liability Company owns 0.11% or 17,385 shares. Maryland Capital Management owns 2.92% or 418,232 shares in its portfolio. Banced has invested 1.04% in Abbott Laboratories (NYSE: ABT). 36,061 were accumulated by Allstate Corporation. 37,825 were accumulated by Harbor Invest Mgmt Limited. Menlo Limited Liability Com accumulated 47,978 shares or 1.71% of the shares. Sva Plumb Wealth Management Ltd Liability invested in 34,915 shares or 0.22% of the shares. Mirador Cap Prtnrs L P owns 6,653 shares or 0.2% of its portfolio. Wetherby Asset Mgmt holds 0.29% or 35,589 shares in its portfolio. Utd Financial Bank reported 131,631 shares.
As of June 15, 2017, it had 0 insider purchases and 1 sale per activity of $ 26,482.
Ratings Coverage of Abbott Laboratories (NYSE: ABT)
Among the 24 badysts covering Abbott Laboratories (NYSE: ABT), 14 are Buy, 0 Sell and 10 Hold. Therefore, 58% are positive. Abbott Laboratories had 87 badyst reports from July 24, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Friday, October 9 with "Outperform". On Tuesday, March 15, Jefferies maintained the rating of the shares with "Buy". The firm has a "Buy" rating awarded by Stifel Nicolaus on Wednesday, April 19. Jefferies held the shares of ABT in a report on Tuesday, September 13 with the rating of "Buy." The firm has a "Buy" rating awarded on Thursday, August 4 by Jefferies. The firm has a "Market Perform" rating granted on Friday, January 29 by William Blair. The firm has a "Buy" rating granted on Friday, February 5 by Argus Research. The firm obtained the "Buy" rating on Thursday, August 27, by Wells Fargo. The firm has a "Buy" rating awarded by Jefferies on Thursday, July 14. The action of Abbott Laboratories (NYSE: ABT) is rated "Equal-Weight" on Thursday, October 19 by Morgan Stanley. Below is a list of the latest ratings and changes in the price targets of Abbott Laboratories (NYSE: ABT).
10/18/2017 Broker: Cowen & Co Rating: Buy new goal: $ 68.0 Hold
10/19/2017 Agent: Barclays Capital Rating: Overweight Old Target: $ 60 New Target: $ 64 Maintain
10/19/2017 Broker: BMO Capital Markets Rating: Market Realize New Target: $ 5.00 Maintain
10/19/2017 Broker: Citigroup Rating: Neutral New goal: $ 5.00 Maintenance
10/19/2017 Agent : Morgan Stanley Rating: Same weight Old goal: $ 5.00 New goal: $ 6.00 Maintenance
10/19/2017 Agent: Stifel Nicolaus Rating: Buy new goal: $ 63.0 Maintain
10/19/2017 Agent: RBC Capital Markets Rating: Buy new goal: $ 60.0 Hold
10/18/2017 Agent: Jefferies Rating: Buy new goal: $ 65.0 Hold
10/10/2017 Agent: Jefferies Rating: Buy New Target: $ 58.0 Maintain
10/06/2017 Broker: JP Morgan Rating: Neutral New Target: $ 60 Maintai n
The share declined 0.69% or $ 0.39 during the last trading session, reaching $ 55.98. Around 5.32 million shares traded. Abbott Laboratories (NYSE: ABT) has risen 15.90% since December 3, 2016 and is trending upward. It has had a performance below 0.80% of the S & P500.
Abbott Laboratories manufactures and sells health care products around the world. The company has a market capitalization of $ 97.44 billion. The company's established pharmaceuticals segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; Irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; Hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever and inflammation; migraines; anti-infectious clarithromycin; cardiovascular and metabolic products; and vaccines against influenza, as well as to regulate the physiological rhythm of the colon. It has a P / E ratio of 78.4. The company's diagnostic products segment provides immunobadays and clinical chemistry systems; tests used to detect and / or diagnose cancer, heart problems, drugs of abuse, fertility, infectious diseases and therapeutic drug control; hematology and reagent systems; diagnostic systems and cartridges; instruments to automate the extraction, purification and preparation of DNA and RNA from patient samples, and to detect and measure infectious agents; genomic tests; computer and automation solutions; and a set of computer tools and professional services.
The latest highlights from Abbott Laboratories (NYSE: ABT) were published by: Investorplace.com, which launched: "Abbott Laboratories (ABT) a Buy on Strong Quant Score" on November 28, 2017, also Investorplace. com with his article: "Trade of the day: Abbott Laboratories (ABT)" published on November 20, 2017, Businesswire.com published: "Global Blood Testing Market 2017-2021 with Abbott Laboratories, Bio-Rad" … "the November 28, 2017. More interesting news about Abbott Laboratories (NYSE: ABT) was published by: Investorplace.com and its article: "Earnings Momentum Make Abbott Laboratories (ABT) a purchase" published on November 21, 2017 also as an article News from Investorplace.com titled: "High Level Revenue Moment Keeping Abbott Laboratories (ABT) a Purchase" with publication date: November 14, 2017.
Receiving news and ratings via email – Enter your Email address below to receive a concise dai summary of the latest news and badyst ratings with our FREE daily newsletter by email.